Skip Navigation LinksHome > February 2009 - Volume 28 - Issue 2 > STEADY-STATE PHARMACOKINETICS OF LOPINAVIR/RITONAVIR IN COMB...
Pediatric Infectious Disease Journal:
doi: 10.1097/INF.0b013e3181861d8b
Brief Reports

STEADY-STATE PHARMACOKINETICS OF LOPINAVIR/RITONAVIR IN COMBINATION WITH EFAVIRENZ IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PEDIATRIC PATIENTS

King, Jennifer R. PharmD*; Acosta, Edward P. PharmD*; Yogev, Ram MD†; Wiznia, Andrew MD‡; Kraimer, Joyce MS§; Graham, Bobbie MS¶; Carey, Vincent PhD∥; Britto, Paula MS∥; Jean-Philippe, Patrick MD**; Moye, John MD††; Watson, Douglas MD‡‡

Collapse Box

Abstract

The pharmacokinetics of lopinavir/ritonavir (LPV/RTV) 300 mg/m2 twice daily and efavirenz (EFV) 350 mg/m2 once daily were evaluated in HIV-infected children. The minimum concentrations for LPV contained values above the target range, and the estimated minimum concentrations for EFV contained values below the range. Our data support the current LPV/RTV dose, but EFV 350 mg/m2 may not be sufficient.

© 2009 Lippincott Williams & Wilkins, Inc.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.